Syncona

Type

Corporate investor

Status

Active

Location

London, United Kingdom

Total investments

42

Average round size

54M

Portfolio companies

22

Rounds per year

3.50

Lead investments

18

Follow on index

0.48

Exits

6

Areas of investment
BiotechnologyHealth CareHealth DiagnosticsWellnessGeneticsMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

In 2012 was created Syncona Partners LLP, which is appeared as VC. The venture was found in Europe in United Kingdom. The main office of represented VC is situated in the London.

The overall number of key employees were 11.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Syncona Partners LLP, startups are often financed by UCL Technology Fund, Sixth Element Capital, Woodford Investment Management. The meaningful sponsors for the fund in investment in the same round are UCL Technology Fund, UCLB, Sixth Element Capital. In the next rounds fund is usually obtained by Woodford Investment Management, UCL Technology Fund, Sequoia Capital.

Considering the real fund results, this VC is 15 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2019. This Syncona Partners LLP works on 17 percentage points less the average amount of lead investments comparing to the other organizations. The typical startup value when the investment from Syncona Partners LLP is 50-100 millions dollars. Deals in the range of 10 - 50 millions dollars are the general things for fund. The higher amount of exits for fund were in 2019. The fund is generally included in 2-6 deals every year.

The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Biopharma. Among the most popular portfolio startups of the fund, we may highlight Gyroscope Therapeutics, Cambridge Epigenetix, Quell Therapeutics. For fund there is a match between the location of its establishment and the land of its numerous investments - United Kingdom. Besides, a startup needs to be aged 2-3 years to get the investment from the fund.

Show more

Investor highlights

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
42
Lead investments
18
Exits
6
Rounds per year
3.50
Follow on index
0.48
Investments by industry
  • Biotechnology (33)
  • Therapeutics (16)
  • Health Care (15)
  • Medical (12)
  • Biopharma (8)
  • Show 13 more
Investments by region
  • United Kingdom (31)
  • Switzerland (3)
  • United States (7)
  • Netherlands (1)
Peak activity year
2019
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
5
Avg. valuation at time of investment
41M
Group Appearance index
0.67
Avg. company exit year
4
Avg. multiplicator
2.29
Strategy success index
0.40

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Gyroscope Therapeutics 26 Mar 2021 Biotechnology, Health Care, Genetics, Therapeutics Late Stage Venture 147M England, United Kingdom, United Kingdom
iOnctura 20 Jun 2024 Biotechnology, Health Care, Medical Device Early Stage Venture 94M Switzerland, Geneva, Geneva
Qrcrypto 25 May 2019 FinTech, Cyber Security, Network Security Seed 1M Switzerland, Vaud, Lausanne
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.